ALK (T1151-L1152insT)

ALK · Variant type: indel · HGVS: p.T1151-L1152insT

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Entrectinib	100.0%	0.0%	93.69
2	Lorlatinib	99.5%	0.5%	97.24
3	Brigatinib	99.4%	0.6%	82.96
4	Gilteritinib	99.3%	0.7%	88.97
5	Repotrectinib	98.7%	1.3%	84.21
6	Ceritinib	97.8%	2.2%	95.44
7	Alectinib	97.0%	3.0%	95.49
8	Crizotinib	96.9%	3.1%	91.39
9	Pralsetinib	95.7%	4.3%	93.43
10	Alpelisib	93.2%	6.8%	97.22
11	Sunitinib	92.1%	7.9%	91.73
12	Ruxolitinib	89.2%	10.8%	98.25
13	Osimertinib	82.2%	17.8%	97.24
14	Nintedanib	81.4%	18.6%	90.23
15	Pacritinib	77.4%	22.6%	88.64
16	Baricitinib	74.7%	25.3%	97.99
17	Tenalisib	63.8%	36.2%	97.98
18	Lazertinib	57.0%	43.0%	97.47
19	Bosutinib	42.8%	57.2%	87.22
20	Fostamatinib	42.1%	57.9%	96.74
21	Upadacitinib	30.1%	69.9%	97.98
22	Defactinib	29.7%	70.3%	92.68
23	Neratinib	22.3%	77.7%	93.18
24	Cabozantinib	21.8%	78.2%	92.73
25	Fedratinib	19.9%	80.1%	96.21

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Entrectinib	100.0%	98.8%	+1.2%
Lorlatinib	99.5%	97.2%	+2.3%
Brigatinib	99.4%	99.2%	+0.2%
Gilteritinib	99.3%	99.5%	-0.1%
Repotrectinib	98.7%	99.4%	-0.7%
Ceritinib	97.8%	98.3%	-0.4%
Alectinib	97.0%	98.6%	-1.5%
Crizotinib	96.9%	97.7%	-0.8%
Pralsetinib	95.7%	82.6%	+13.1%
Alpelisib	93.2%	80.7%	+12.6%
Sunitinib	92.1%	87.7%	+4.5%
Ruxolitinib	89.2%	52.1%	+37.1%
Osimertinib	82.2%	80.5%	+1.7%
Nintedanib	81.4%	84.9%	-3.5%
Pacritinib	77.4%	55.3%	+22.1%
Baricitinib	74.7%	46.4%	+28.3%
Tenalisib	63.8%	45.2%	+18.5%
Lazertinib	57.0%	46.3%	+10.7%
Bosutinib	42.8%	75.1%	-32.3%
Fostamatinib	42.1%	—	—
Upadacitinib	30.1%	—	—
Defactinib	29.7%	—	—
Neratinib	22.3%	—	—
Cabozantinib	21.8%	—	—
Fedratinib	19.9%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 16.2ms